Kerri Fitzgerald

DocwireNews

<p>The U.S. Food and Drug Administration (FDA) approved the <a href="https://www.docwirenews.com/docwire-pick/biosimilars-overview-relevance/">biosimilar agent</a> Ziextenzo&trade; (pegfilgrastim-bmez) to decrease the incidence of febrile neutropenia in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.<p>This agent has demonstrated similarity between Neulasta&reg; (pegfilgrastim), the <a href="https://www.docwirenews.com/resource-center/biosimilar/biosimilar-formulary-evaluation-pharmacists-guide/">biologic reference product</a>.</p><h2>No clinically significant differences</h2><p>The approval was based on analytical, preclinical, and clinical research, including data from a pivotal three-way pharmacokinetics (PK) and pharmacodynamics (PD) study that compared pegfilgrastim-bmez with the reference product pegfilgrastim. PK and PD similarity were demonstrated in all three comparisons, and there were no clinically meaningful differences observed regarding safety and immunogenicity among the treatment groups.</p><p>Pegfilgrastim-bmez has been approved and marketed in Europe since 2018. The FDA previously approved another biosimilar for febrile neutropenia, Zarxio&reg; (filgrastim-sndz).</p></p>


Connie Rhee, MD

Joel M. Topf, MD, FACP

CKD Management and Cognition

NKF Spring Clinical Meetings 2025

Bradley Marder, MD

Gout Studies: Transplant Waitlisting and Bone Erosion

Jayme Locke, MD, MPH

The Promise of Xenotransplantation

Latest News

FDA Approves Another Biosimilar for Febrile Neutropenia

Oncology

The U.S. Food and Drug Administration (FDA) approved the biosimilar agent Ziextenzo™ (pegfilgrastim-bmez) to decrease the incidence of febrile neutropenia in patients with ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe